Deutivacaftor + Tezacaftor + Vanzacaftor 10 mg + 50 mg + 125mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 10 mg + 50 mg + 125mg

Reference Brands: Alyftrek (USA)

Category: Orphan Drugs

Deutivacaftor + Tezacaftor + Vanzacaftor is a Orphan Drugs product available as Tablets in strengths 10 mg + 50 mg + 125mg. It corresponds to the reference brand Alyftrek (USA). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Product Description:

Alyftrek is a fixed-dose combination oral medication containing vanzacaftor, tezacaftor, and deutivacaftor, developed for the treatment of cystic fibrosis (CF). The drug is specifically indicated for patients aged six years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Vanzacaftor, formulated as vanzacaftor calcium dihydrate, and tezacaftor help improve the processing and trafficking of the defective CFTR protein to the cell surface, while deutivacaftor enhances its function by increasing channel opening probability.

By acting on the underlying genetic defect, Alyftrek improves chloride transport across epithelial cell membranes, helping to hydrate mucus in the lungs and digestive tract. This leads to improved lung function, reduced pulmonary exacerbations, and better overall symptom management in eligible patients. Administered orally once daily, the medication offers a convenient and effective treatment option for cystic fibrosis, supporting long-term disease management and enhancing quality of life. Alyftrek represents a next-generation therapy for CF, providing targeted correction of CFTR protein function in patients with responsive mutations.